Researchers at Monash University have discovered why some intestinal worm infections become chronic in animal models, which could lead to human vaccinations and better therapies. Parasitic worms, also called helminths, usually infect the host by living in the gut. About a quarter of the world’s population is afflicted with helminth infections. They are highly prevalent in developing countries such as sub-Saharan Africa, South America and some tropical countries in Asia. In Australia, they can be a problem in First Nations communities.
Some people can fight off the parasites due to effective immune responses. Some people who fail to develop effective immune responses suffer from a long-lasting chronic infection.
Published in Mucosal Immunology, the Monash Biomedicine Discovery Institute study used animal models to reveal a protective immune feature that may be lacking in people who are chronically infected. They discovered that a group of immune cells called T follicular helper (TFH) cells behaved very differently at cellular and molecular levels during acute, resolving and chronic helminth infection. This meant that in some models the cells protected against chronic illness but in others they didn’t. First author Dr Aidil Zaini said blocking the TFH response impaired worm clearance and promoted chronic infection, so the key was to develop ways to facilitate the protective mechanism.
He said humans also had varying immune responses, so further investigation could develop ways of protecting those prone to chronic disease.
“Our findings provide a proof-of-concept that harnessing the protective features of these immune cells may pave the way for the development of human vaccines and new drugs against helminths,” Dr Zaini explained.
“Although conventional deworming drugs can help clear the parasites, they fail to provide long-term protection and are likely to be less effective due to the development of resistance against these drugs by the parasites.” Dr Zaini said the results were promising and warranted further investigation. He said the ultimate therapeutic goal was to develop effective vaccines against parasitic helminths in humans, which were not yet available.
“Our discovery contributes to the growing body of literature on the protective immune features during helminth infection,” Professor Zaph said.
“This knowledge can be further explored to facilitate the development of long-term immune interventions for helminth infections, as well as diseases such as allergy. Interestingly, our immune system evolves into developing a similar type of immune response during both helminth infection and allergic responses.”